Agilent Announces Favorable Legal Ruling from European Patent Office
News Dec 27, 2012
Agilent Technologies Inc. has announced a favorable legal ruling from the European Patent Office regarding Agilent’s opposition to patent EP 0853679, assigned to Affymetrix.
On Oct. 21, 2003, Agilent joined Combimatrix and Clonediag in opposing the patent, titled “Expression Monitoring by Hybridization to High Density Oligonucleotide Arrays.”
Agilent opposed the breadth of the patent, particularly the patent’s broad use of the term “control probe” in connection with gene-expression microarrays. Gene-expression microarrays are part of Agilent’s portfolio of products for genetic research.
An opposition hearing was held on Sept. 12, 2006. During the hearing the patent claims were narrowed, but Agilent and Clonediag still believed them to be overbroad and vague.
After the written findings were issued on May 11, 2009, Agilent appealed. An appeal hearing was held July 5, 2012, resulting in this ruling, with all EP 0853679 claims rejected and the patent revoked in totality.
“This ruling is a very positive result for Agilent’s many European gene-expression microarray customers and the entire European gene-expression community,” said Robert Schueren, Agilent vice president, Genomics.
“The ruling allows customers to continue using established workflows and protocols, including control probes, without having to worry about potential patent infringement.”
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.